A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

August 19, 2022

Study Completion Date

December 22, 2022

Conditions
Neurodegenerative Diseases
Interventions
DRUG

NS101 IV infusion

Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.

Trial Locations (1)

Unknown

Syneos Health, Québec

Sponsors
All Listed Sponsors
lead

Neuracle Science Co., LTD.

INDUSTRY

NCT05143463 - A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion | Biotech Hunter | Biotech Hunter